Pfizer’s Tourmaline Bio TRML Stock Holding History

Pfizer’s Portfolio TRML Stock Details TRML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1,272,214	Closed	-$60.8M	–	21
2025 Q3	$60.8M	Hold	1,272,214	–	–	13.91%	3
2025 Q2	$20.3M	Hold	1,272,214	–	–	3.53%	5
2025 Q1	$19.4M	Hold	1,272,214	–	–	3.86%	5
2024 Q4	$25.8M	Buy	+1,272,214	New	+$32M	1%	6

Pfizer's TRML Position: Q4 2025 in Review

Pfizer sold out of Tourmaline Bio (TRML) in Q4 2025, closing a stake of 1,272,214 shares — an estimated $60.8M sold.

Pfizer first reported a position in TRML in Q4 2024 and held it in 4 quarters. The position peaked at $60.8M in Q3 2025. 0 funds tracked by Wall St. Rank hold TRML as of Q4 2025.

Pfizer reported no remaining Tourmaline Bio position as of Q4 2025 after selling out during the quarter.
Pfizer sold 1,272,214 Tourmaline Bio shares in Q4 2025, an estimated $60.8M.
Pfizer first reported a position in Tourmaline Bio in Q4 2024 and held it in 4 quarters.
Pfizer's Tourmaline Bio position peaked at $60.8M in Q3 2025.
0 funds tracked by Wall St. Rank held Tourmaline Bio as of Q4 2025.

Based on Pfizer's 13F filing for Q4 2025, filed 12 Feb 2026.